Redeye is surprised to hear that CEO Axel Berntsson is leaving the company to take on the role as CE...
Redeye provides its initial take on Mentice’s Q2 2024 report, which exceeded our estimates.
- Q2 EBITDA beating by 9-13% on product mix, scale and cost focus - Guidance hiked despite continued...
Ahead of its Q2 results on 6 August, we remain positive about NoHo's relative performance in a muted...
Redeye comments on W5 Solutions Q2-results which were weaker than estimated owing to a soft topline ...
Redeye returns with an updated take following a solid Q2 report from Stille, showing very minor devi...
- Weak Q2, -6% on sales and -25% on adj. EBIT vs ABGSCe - FCF generation held back by R&D capitalisa...
Redeye is making some minor downward adjustments to our financial forecasts, following the Q2 report...
We keep our estimates intact ahead of CapMan’s Q2 report due on 8 August.
Både omsättning och resultat stärktes under kvartalet, vilket förstärker vår syn om en positiv resul...
Fastighetsbolaget Trianons driftnetto ökade till 134,0 (130,6) miljoner kronor under det andra kvart...
Consti’s Q2 results beat our estimates for both net sales and EBIT.
- 25% miss on adj EBIT - Lower on sales and weaker gross margin - Estimates likely down 5-8% on adj.
- 3% organic growth to accelerate to 18-16% H2'24e - 22% adj.
Redeye offers an update on Advenica following the company's Q2 report.
Vitrolife delivered a surprising organic growth recovery with 4% organic growth and even if there wa...
Redeye thinks the Q2 report was strong in all aspects.
Redeye comments on last week’s positive decision for patent ‘879.
Redeye updates on Invisio post Q2-results which came in above our forecast owing to larger than expe...
- Sales decline 6% y-o-y as EBIT remains at break-even - Weak restaurant and hotel market hamper NW&...
